When to take AOD-9604 peptide: timing that actually matters

Last updated 2026-07-25

What is the actual timing question people are asking about AOD-9604?

People want to know if AOD-9604 works better taken in the morning, at night, fasted, or around workouts. That's a fair question to ask about any peptide with a short half-life. But it's worth separating two things: what the fasted-state theory predicts, and what the human trial data actually showed. AOD-9604 is a 15-amino-acid fragment of the C-terminal region of human growth hormone (hGH), specifically the 176-191 fragment, built on the idea that this piece of the hGH molecule carries the fat-metabolizing signal without the growth-promoting or blood-sugar effects of full-length hGH. That's the whole commercial pitch. It's a clean idea. The problem is that the trial record for the actual weight-loss endpoint didn't back it up convincingly, a point we'll come back to because it matters more than any timing decision you'll make. So if you're asking "when should I inject this," the honest answer has two layers. Layer one is the practical, half-life-driven logic that most fragment and peptide protocols use. Layer two is a bigger caveat: timing optimization on top of a compound whose core efficacy signal is weak is optimizing the wrong variable.

Should you take AOD-9604 on an empty stomach or with food?

Most sourcing guides and older bodybuilding-forum protocols recommend taking AOD-9604 fasted, meaning no food for roughly 30 to 60 minutes before and after the injection. The logic borrows directly from growth hormone secretagogue dosing: insulin release from a meal is believed to blunt the intended lipolytic (fat-releasing) signaling pathway that the fragment is supposed to mimic. That logic is plausible on paper. Insulin does suppress lipolysis, and if AOD-9604 genuinely triggers a lipolytic cascade the way full hGH's C-terminal fragment is theorized to, a fed state with high circulating insulin would work against that. But there's no human dosing-timing study in the record that isolates fasted versus fed AOD-9604 injection and measures fat loss outcomes separately. The fasted protocol is inference from HGH secretagogue pharmacology, not a finding specific to this fragment. If you're going to use it anyway, fasted administration in the morning or before training is the more defensible choice based on that mechanistic reasoning. Just don't mistake "defensible reasoning" for "proven timing."

Is morning or nighttime dosing better for AOD-9604?

There's no published human trial comparing morning versus evening AOD-9604 dosing for fat loss outcomes, so any specific claim about one being superior is a guess dressed up as protocol. The morning-fasted argument mirrors HGH-releasing peptide logic: natural growth hormone pulses are highest during early sleep and in the hours after waking, and some users try to "stack" AOD-9604 timing around those windows on the theory it may complement the body's own hGH rhythm. Others prefer splitting doses, one in the morning and one before bed, again based on user-forum tradition rather than clinical evidence. What actually has trial-level scrutiny behind it is the broader efficacy question, and that's where the caveats concentrate. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile discusses its development as a fragment-based obesity therapeutic candidate, distinct from full hGH, built around the C-terminal lipolytic domain ^[1]. A separate 2006 review of obesity drugs in clinical development places AOD-9604 among the compounds being tested in that era's obesity pipeline ^[2]. Neither of these sources, nor the trial record more broadly, gives you grounds to prefer one clock time over another.

How does AOD-9604 timing relate to training or workouts?

Some protocols suggest injecting AOD-9604 30 to 60 minutes before exercise, again on the fasted-lipolysis theory: the idea is that combining a workout-driven catecholamine response with the fragment's proposed fat-mobilizing signal could be additive. That's a hypothesis, not a demonstrated effect in humans. It borrows logic from research on growth hormone and exercise-induced lipolysis generally, not from AOD-9604-specific pre/post-workout trial data. If you're already using AOD-9604 how to inject as your technique reference, the pre-workout fasted window is a reasonable default to pick, mainly because it's easy to remember and keeps you consistent, not because a study proved it superior to post-workout or rest-day dosing.

What does the actual human trial evidence say about AOD-9604 for fat loss?

This is the part that should shape your decision more than any clock-time question. AOD-9604 went through Phase II human obesity trials in the 2000s, and the weight-loss results did not separate convincingly from placebo. That is the central, documented fact in the trial record, and it's the reason regulatory approval never followed for an obesity indication. The compound's own developmental record, tracked across obesity-drug pipeline reviews, shows it moving through early-phase and mid-phase testing without producing the kind of clean, replicated fat-loss signal that gets a drug to FDA approval ^[2]. You can check the FDA's own approved-drug database directly: AOD-9604 does not appear as an approved product [FDA Drugs@FDA, accessed 2026], which tells you plainly where the regulatory story landed. The fragment rationale itself, that you can isolate the fat-metabolizing piece of hGH's C-terminus and get a fat-loss effect without hGH's other actions, is a genuinely clever piece of peptide biochemistry. The 2004 review in Current Opinion in Investigational Drugs documents this metabolic rationale in detail ^[1]. But a clean rationale and a clean trial result are two different things, and only one of those materialized here. If you want the full trial-by-trial breakdown, read aod 9604 peptide, which is our evidence hub page on this exact question. So before you plan injection timing around workouts or fasting windows, sit with this: no timing protocol fixes an efficacy signal that didn't separate from placebo in the actual human obesity studies. Timing optimization on a weak-efficacy compound is polishing a variable that isn't the bottleneck.

How often should you dose AOD-9604, and does frequency matter more than time of day?

Frequency matters more than clock time, if you're going to use it at all. Common protocols call for once-daily dosing, most often in the morning fasted, though some sourcing guides describe twice-daily splitting. There's no comparative human trial isolating once-daily versus twice-daily AOD-9604 dosing for fat-loss outcomes, so frequency recommendations you'll find online come from user tradition and general peptide half-life logic rather than a study arm. Half-life is short for this class of fragment peptide, which is the stated reason behind daily (rather than weekly) dosing schedules in the protocols people share. If you're weighing frequency against a reconstitution and storage plan, how to reconstitute AOD-9604 covers the practical side of keeping a multi-week supply stable, which matters more for consistency than hitting an exact hour each day.

Does AOD-9604 show up on a drug test, and does that affect when you'd use it?

If you're an athlete under WADA testing rules, timing relative to competition matters for a different reason than fat-loss optimization: detection windows. A 2013 study in Drug Testing and Analysis specifically examined whether AOD-9604 interferes with the WADA hGH isoform immunoassay and found it does not influence that test ^[3], meaning the standard hGH screening method isn't confounded by AOD-9604's presence, but that doesn't mean AOD-9604 itself is undetectable through other methods. Separate mass-spectrometry-based approaches have been developed specifically to catch small peptides like this. A 2016 paper in the Journal of Separation Science describes a direct urine-injection, liquid chromatography, and ion mobility mass spectrometry method built to screen for peptides under 2 kDa, the size class AOD-9604 falls into ^[4]. Broader reviews of doping-control analytics, including a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting emerging therapeutics and non-approved drugs ^[5], and a 2014 review in Expert Review of Proteomics on detecting peptidic drugs and analogs in sports doping ^[6], both describe the ongoing arms race between small-peptide manufacturers and detection labs. If you're competing under any drug-tested federation, assume detectability, not immunity, and plan timing around your testing calendar rather than a metabolic theory.

What's a realistic AOD-9604 protocol if you're going to try it anyway?

If you've read the trial caveats and still want to proceed, the most common protocol structure looks like this: a single subcutaneous injection in the morning, fasted, five to seven days a week, for a defined cycle length (often 8 to 12 weeks in user-shared protocols), with dose typically in the 250-500 mcg range per injection according to sourcing-site product guidance rather than a clinical dosing study. None of those numbers come from a phase III dosing trial establishing an optimal regimen, because that trial never produced the approval-grade result needed to establish one. What you're following is a community consensus protocol, not a prescribing label. If you go this route, pair it with a real log: track waist measurement, weight, and how you feel weekly, and set a stop-loss point (say, four weeks with zero measurable change) before you keep spending money on it.

How does AOD-9604 compare to options with better human evidence?

This is worth asking before timing at all. Tesamorelin is FDA-approved, specifically for HIV-associated lipodystrophy, with actual approval-grade trial data behind that indication, which is a meaningfully different evidence tier than AOD-9604's unapproved, placebo-matched Phase II record. That doesn't mean tesamorelin is a general fat-loss drug for everyone, its approval is indication-specific, but the comparison is instructive: one compound cleared the bar that generates FDA approval, the other didn't. If you want the full side-by-side, aod 9604 vs tesamorelin breaks down the mechanism, evidence quality, and practical differences in more depth than timing questions can capture.

Where does AOD-9604 legally sit, and does that affect sourcing or timing decisions?

AOD-9604 is not on the FDA's current 503A bulk drug substances list, meaning it's not on the approved list for traditional pharmacy compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) ^[7]. The FDA maintains that 503A bulks list under 21 CFR 216.23 ^[8], and a separate 503B list for outsourcing facilities under 21 CFR 216.24 ^[9]. The FDA's own bulk drug substances guidance page for 503A compounding lays out how substances get nominated and reviewed for that list ^[10], and the current nominated-substances list is public ^[11]. That regulatory status shapes how AOD-9604 gets sold in practice: research-use framing, not a prescribed dosing schedule from a pharmacist. Under 21 CFR 201.128, the FDA's rule on "intended use" determines how a product's labeling and marketing establish what it's legally sold for ^[12], which is exactly why legitimate research-focused sellers avoid making direct human-dosing or treatment claims. If you're sourcing it, best place to buy aod 9604 and aod-9604 peptide for sale cover how to vet a supplier against that backdrop, including checking for third-party testing documentation rather than trusting label claims alone.

What should shape your actual decision more than injection timing?

Three things matter more than picking a time of day: whether you've read the actual trial outcomes and accept that placebo-level weight loss is the documented result, whether you have a legitimate sourcing channel with verifiable testing, and whether you're comparing against options like tesamorelin that have a stronger approval-grade evidence base behind them. AOD-9604 Co reviews providers so you're not guessing at purity or sourcing quality if you decide to move forward, and we point toward the provider-reviewed route with a named fulfilling pharmacy partner rather than leaving you to vet unknown vendors cold. But no amount of good sourcing changes what the Phase II obesity trials showed. Get that part straight first, then worry about the clock.

Frequently asked questions

Is it better to take AOD-9604 in the morning or at night?

There's no human trial comparing morning versus night dosing for AOD-9604 specifically. Morning fasted dosing is the more common protocol, based on general HGH-secretagogue logic about insulin suppressing lipolysis, but this is inference from related compounds, not a finding proven for AOD-9604 itself in a controlled study.

Should AOD-9604 be taken before or after a workout?

Most user protocols suggest 30 to 60 minutes before exercise, fasted, on the theory that exercise-driven catecholamine release might add to the fragment's proposed fat-mobilizing signal. No AOD-9604-specific trial has tested pre- versus post-workout timing, so this is a plausible guess, not established science.

Does AOD-9604 need to be taken on an empty stomach?

Fasted administration (30-60 minutes before and after eating) is the standard recommendation in most sourcing protocols, based on the idea that insulin from food blunts lipolytic signaling. No dedicated fasted-versus-fed human study on AOD-9604 exists to confirm this improves outcomes.

How many times a day should you inject AOD-9604?

Once-daily dosing is most common in shared protocols, usually morning and fasted. Some protocols split into twice-daily doses. No comparative trial has tested once- versus twice-daily dosing for fat-loss outcomes, so frequency guidance here comes from user tradition, not clinical data.

Did AOD-9604 actually work for weight loss in human trials?

AOD-9604 went through Phase II human obesity trials in the 2000s, and the weight-loss results did not separate convincingly from placebo. That's the central documented outcome, and it's why the compound never reached FDA approval for an obesity indication ^[2]. It does not appear in FDA's Drugs@FDA approved-product database.

Is AOD-9604 FDA approved?

No. AOD-9604 is not listed as an FDA-approved drug in the Drugs@FDA database, and it is not on the FDA's 503A bulk drug substances list used for traditional pharmacy compounding ^[7][11]. It is sold through channels that frame it for research use rather than as a prescribed therapy.

Will AOD-9604 show up on a WADA drug test?

A 2013 study found AOD-9604 does not interfere with the WADA hGH isoform immunoassay, meaning it doesn't confound that specific screening test ^[3]. However, other mass-spectrometry-based methods have been developed specifically to detect small peptides like AOD-9604, so assume it's detectable through other analytical routes ^[4][6].

How long does an AOD-9604 cycle typically last?

Community protocols commonly describe 8 to 12 week cycles, but this length comes from user-shared practice, not a clinical trial establishing an optimal duration. No approval-grade dosing study exists to confirm a specific cycle length improves outcomes.

What is the fragment rationale behind AOD-9604 supposed to mean?

AOD-9604 is a 15-amino-acid fragment of the C-terminal region (176-191) of human growth hormone, designed to isolate the fat-metabolizing signal of hGH without its growth-promoting or blood-sugar effects. The idea is sound biochemistry, documented in a 2004 review ^[1], but the human obesity trial results didn't confirm a clean fat-loss effect.

Is tesamorelin a better option than AOD-9604 for fat loss?

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy, backed by approval-grade trial data, a meaningfully stronger evidence tier than AOD-9604's unapproved Phase II record that didn't separate from placebo. Tesamorelin's approval is indication-specific, not a general fat-loss approval, so compare the two carefully rather than assuming either is a universal solution.

Does taking AOD-9604 fasted actually improve fat loss results?

There's no AOD-9604-specific human trial testing fasted versus fed dosing against a fat-loss endpoint. The fasted recommendation is borrowed reasoning from HGH secretagogue pharmacology (insulin suppresses lipolysis), not a demonstrated result for this fragment in controlled human testing.

Where can you find a reviewed source for AOD-9604 if you decide to try it?

AOD-9604 Co reviews providers and points toward a provider-reviewed sourcing route with a named fulfilling pharmacy partner, rather than leaving buyers to vet unknown vendors alone. Check testing documentation and supplier transparency regardless of which channel you use.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's metabolic rationale and development as a fragment-based obesity therapeutic distinct from full hGH.
2. PubMed, Current Opinion in Investigational Drugs (2006): Places AOD-9604 among obesity drugs in clinical development in the 2000s, tracking its pipeline status.
3. PubMed, Drug Testing and Analysis (2013): Found AOD-9604 does not influence the WADA hGH isoform immunoassay.
4. PubMed, Journal of Separation Science (2016): Describes a direct urine-injection LC/ion mobility mass spectrometry method built to screen for peptides under 2 kDa, including small fragments like AOD-9604.
5. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs in doping controls.
6. PubMed, Expert Review of Proteomics (2014): Reviews methods for detecting peptidic drugs, drug candidates, and analogs in sports doping.
7. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Establishes the federal statute governing traditional pharmacy compounding under section 503A.
8. eCFR, 21 CFR 216.23: Defines the 503A bulk drug substances list that AOD-9604 is not currently included on.
9. eCFR, 21 CFR 216.24: Defines the separate 503B bulks list for outsourcing facility compounding.
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Explains the FDA process for nominating and reviewing substances for the 503A bulks list.
11. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Current FDA list of nominated bulk drug substances, used to confirm AOD-9604's regulatory listing status.
12. eCFR, 21 CFR 201.128: Defines how a product's labeling and marketing establish its legal 'intended use,' relevant to research-use-only sourcing language.